LENSAR, Inc. (LNSR)
NASDAQ: LNSR · Real-Time Price · USD
14.11
-0.02 (-0.11%)
Apr 1, 2025, 10:19 AM EDT - Market open

Company Description

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System.

The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.

It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room.

LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR, Inc.
LENSAR logo
Country United States
Founded 2004
Industry Medical Devices
Sector Healthcare
Employees 140
CEO Nicholas Curtis

Contact Details

Address:
2800 Discovery Drive
Orlando, Florida 32826
United States
Phone 888 536 7271
Website lensar.com

Stock Details

Ticker Symbol LNSR
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001320350
CUSIP Number 52634L108
ISIN Number US52634L1089
Employer ID 32-0125724
SIC Code 3841

Key Executives

Name Position
Nicholas T. Curtis President, Chief Executive Officer and Director
Thomas R. Staab II, CPA Chief Financial Officer and Secretary
Alan B. Connaughton Chief Operating Officer
Kendra W. Wong Principal Accounting Officer

Latest SEC Filings

Date Type Title
Mar 25, 2025 SCHEDULE 13D/A Filing
Mar 24, 2025 DFAN14A Filing
Mar 24, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 24, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 24, 2025 8-K Current Report
Feb 28, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals